Rate My Professor Shereen El Nabhani

Shereen Nabhani-Gebara is Professor of Cancer at Kingston University London, within the School of Life Sciences, Pharmacy and Chemistry. She holds a Doctorate in Pharmacy (PharmD), Board Certification in Oncology Pharmacy (BCOP), Senior Fellow of the Higher Education Academy (SFHEA) status, and is a Registered Pharmacist in the USA. Her career encompasses significant roles in academia and professional organizations, including Vice-Chair of the British Oncology Pharmacy Association (BOPA) executive committee and Associate Editor of BMJ Oncology. These positions have amplified her influence in shaping cancer practice and national cancer strategies. Nabhani-Gebara's expertise lies in evaluating healthcare innovations to enhance patient outcomes through technology and by addressing health inequalities. She leads needs assessment studies in EU-funded projects employing mixed-method approaches to develop implementation strategies for service improvements, validated through pilot and feasibility studies. Her research portfolio spans technology-enabled care, artificial intelligence applications in cancer imaging, equity, diversity, and inclusion in oncology pharmacy practice, and the environmental impact of anticancer drugs.

Over the past decade, she has secured successive funding from Innovate UK and international bodies such as FP7 and H2020, resulting in publications as lead author in multiple Q1 journals. Notable works include 'Occurrence of anticancer drugs in the aquatic environment: a systematic review' (Nassour et al., 2020), 'Investigating the efficacy of osimertinib and crizotinib in phase 2 clinical trials on anti-cancer treatment-induced cardiotoxicity' (Kobat et al., 2023), 'Artificial intelligence for optimizing cancer imaging: user experience study' (Hesso et al., 2024), and 'Equity, diversity, and inclusion in oncology pharmacy practice: everyone's business' (Dettwiller et al., 2024). Her contributions extend to assessing adherence in asthma and COPD patients, stability of chemotherapy drugs in elastomeric devices, and experiences of cancer survivors from diverse ethnic backgrounds. Recent projects investigate AI-driven bias in cancer care and inclusive cancer screening campaigns, presented at BOPA conferences.